DLA Piper advises Evers sale to Bright Future Pharma Labs
Pinnenberg — The pharmaceutical factory Evers GmbH & Co KG sells to the Chinese company Bright Future Pharmaceutical Laboratories Ltd. The company produces mainly natural medicines for the urology and gastroenterology sector, which are sold internationally and very strongly on the Asian market, especially in Japan and China. The parties have agreed not to disclose the purchase price.
The family business Pharmazeutische Fabrik Evers GmbH & Co KG was founded in 1933. Headquartered in Pinneberg, near Hamburg, Germany, the company focuses on a selected range of natural medicines for the urology and gastroenterology sectors and acts as a licensor in several countries. The Eviprostat S, Eviprostat N and Gallith brands are among the established products in this field.
Established in 1993, Bright Future Pharmaceutical Laboratories Ltd is the largest GMP (Good Manufacturing Practice) certified pharmaceutical manufacturer in Hong Kong. The company, with more than 7,000 employees, provides people with access to medicines at affordable prices and is particularly active in key growth markets such as Hong Kong, mainland China, North America, Africa, Southeast Asia and Europe.
Advisors to Evers GmbH & Co KG: DLA Piper
The transaction once again underlines the extensive experience of the DLA Piper German China Desk, this time on the German seller side.
The core team of DLA Piper under the leadership of partner Dr. Nils Krause (photo ) continued to consist of senior associate Dr. Jan-Philipp Meier and associates Dr. Jasper von Georg and Ronja Hecker (all Corporate, Hamburg). In addition, Partner Guido Kleve, Counsel Dr. Thilo Streit (both Litigation and Regulatory, Cologne) and Christian Lonquich (Real Estate, Frankfurt) as well as Transaction Lawyer Hui Hao (Corporate, Hamburg) were part of the team.